Asbury, NJ, United States of America

Gerald D Artman, Iii

USPTO Granted Patents = 5 

Average Co-Inventor Count = 13.5

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Gerald D. Artman, III: Innovator in Antiproliferative Compounds

Introduction

Gerald D. Artman, III is a notable inventor based in Asbury, New Jersey. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antiproliferative compounds. With a total of five patents to his name, Artman has demonstrated a commitment to advancing medical science and improving treatment options for patients.

Latest Patents

One of Artman's latest patents focuses on antiproliferative compounds and methods of use thereof. This patent includes a specific compound, 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, along with its enantiomers, mixtures, tautomers, and pharmaceutically acceptable salts. The patent outlines methods for treating, preventing, or managing multiple myeloma using these compounds. Additionally, it describes pharmaceutical compositions that incorporate these compounds and methods for their use.

Career Highlights

Gerald D. Artman, III is currently associated with Celgene Corporation, a leading biopharmaceutical company. His work at Celgene has allowed him to focus on innovative research and development in the pharmaceutical sector. Artman's expertise in antiproliferative compounds has positioned him as a key contributor to advancements in cancer treatment.

Collaborations

Artman has collaborated with several esteemed colleagues, including Hon-Wah Man and Paula Alessandra Tavares-Greco. These collaborations have fostered a productive environment for innovation and have contributed to the successful development of new therapeutic compounds.

Conclusion

Gerald D. Artman, III is a distinguished inventor whose work in antiproliferative compounds has the potential to significantly impact cancer treatment. His contributions to the field, along with his collaborations at Celgene Corporation, highlight his dedication to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…